Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Dyne Therapeutics Q4 EPS $(1.09) Misses $(0.92) Estimate, Cash Balance of $123.1M

Author: Benzinga Newsdesk | March 05, 2024 08:36am
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.92) by 18.48 percent. This is a 47.3 percent decrease over losses of $(0.74) per share from the same period last year.

Posted In: DYN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist